Henry Schein’s (HSIC) Outperform Rating Reiterated at Barrington Research

Barrington Research reissued their outperform rating on shares of Henry Schein (NASDAQ:HSIC) in a report published on Tuesday,Benzinga reports. Barrington Research currently has a $78.00 price target on the stock.

Several other brokerages have also commented on HSIC. JPMorgan Chase & Co. cut their price target on shares of Henry Schein from $80.00 to $76.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Evercore ISI upgraded shares of Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price target on the stock in a research note on Tuesday, August 26th. Leerink Partners set a $75.00 price target on shares of Henry Schein in a research note on Monday, July 14th. Robert W. Baird reiterated a “neutral” rating and set a $72.00 price target (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Finally, UBS Group cut their price target on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $76.67.

Henry Schein Price Performance

Henry Schein stock opened at $65.64 on Tuesday. The stock has a market cap of $7.96 billion, a P/E ratio of 21.17, a price-to-earnings-growth ratio of 2.23 and a beta of 0.86. The company has a fifty day simple moving average of $68.56 and a 200-day simple moving average of $69.20. Henry Schein has a 12-month low of $60.56 and a 12-month high of $82.49. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same period last year, the firm posted $1.23 earnings per share. Henry Schein’s revenue for the quarter was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Equities analysts expect that Henry Schein will post 4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Henry Schein by 3.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock valued at $341,000 after buying an additional 157 shares during the period. Equitable Trust Co. raised its stake in Henry Schein by 3.1% during the second quarter. Equitable Trust Co. now owns 5,317 shares of the company’s stock worth $388,000 after purchasing an additional 158 shares during the period. CW Advisors LLC raised its stake in Henry Schein by 2.8% during the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after purchasing an additional 163 shares during the period. TD Asset Management Inc raised its stake in Henry Schein by 0.8% during the second quarter. TD Asset Management Inc now owns 22,016 shares of the company’s stock worth $1,608,000 after purchasing an additional 164 shares during the period. Finally, Radnor Capital Management LLC raised its stake in Henry Schein by 1.6% during the second quarter. Radnor Capital Management LLC now owns 11,415 shares of the company’s stock worth $834,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.